Welcome to our dedicated page for Opko Health SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OPKO Health filings document formal disclosures for a public biopharmaceutical and diagnostics company with pharmaceutical operations, BioReference diagnostic testing, and research programs at ModeX Therapeutics. Its 8-K reports cover operating and financial results, financial guidance, business updates, material agreements, collaborations, and capital-structure matters.
Proxy filings describe governance, shareholder voting matters, executive compensation, and equity-award disclosures. Other material-event reports document completed corporate actions, including the sale of certain BioReference oncology and oncology-related clinical testing assets, along with Regulation FD disclosures and exhibits attached to quarterly and annual business updates.
OPKO Health’s major shareholder Phillip Frost reports beneficial ownership of 255,429,406 shares of common stock, or about 34.1% of shares outstanding. This reflects holdings through Gamma Trust, Frost Nevada Investments Trust, a philanthropic foundation, stock options and restricted stock units.
The amendment is being filed solely because OPKO’s outstanding share count changed to 746,328,225 as of June 29, 2026. Frost and affiliated trusts report no transactions in OPKO common stock during the 60 days before this amendment.
OPKO Health director Prem A. Lachman received a new stock option grant. On June 18, 2026, he was awarded options for 30,000 shares of OPKO Health common stock at an exercise price of $1.42 per share. These options are compensation-related, not an open-market purchase, and bring his directly held option position reported in this filing to 30,000 derivative shares.
OPKO Health director Roger Medel received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. Following this grant, he holds 30,000 options directly.
OPKO HEALTH, INC. director John A. Paganelli received a grant of stock options for 30,000 shares of common stock as compensation. The options have an exercise price of $1.42 per share, become exercisable starting on 2027-06-18, and expire on 2036-06-17. Following this grant, he holds 30,000 options directly.
OPKO HEALTH, INC. director Richard C. Pfenniger Jr. received a grant of stock options representing 60,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. After this award, he holds 60,000 derivative securities directly.
OPKO HEALTH director Uppaluri Subbarao V received a grant of stock options covering 80,000 shares of common stock as part of standard director compensation. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036.
According to the footnote, on June 18, 2026 the company canceled a prior grant of 50,000 options, granted 30,000 new options, and reissued 50,000 options, resulting in 80,000 options held directly after this award.
OPKO HEALTH, INC. director Alice Lin-Tsing Yu received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, were granted on June 18, 2026, and become exercisable starting June 18, 2027 with an expiration date of June 17, 2036. Following this grant, she holds stock options for 30,000 shares directly.
OPKO Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Stockholders elected eleven directors, each receiving more votes "For" than "Against", including Phillip Frost, M.D. with 423,666,978 votes for and 40,175,942 against.
Stockholders approved the Company’s 2026 Equity Incentive Plan, with 440,096,997 votes for and 23,694,041 against. They also approved, on a non-binding advisory basis, the compensation of the named executive officers, with 446,238,170 votes for and 17,487,326 against.
In addition, stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 535,070,921 votes for and 6,120,699 against. No other matters were considered or voted upon at the meeting.
OPKO Health is calling a virtual 2026 annual stockholder meeting on June 18, 2026, asking investors to elect 11 directors, approve a new 2026 Equity Incentive Plan, give an advisory Say on Pay vote, and ratify Ernst & Young LLP as auditor for 2026.
Stockholders of record on April 20, 2026, holding 755,092,256 outstanding common shares, are entitled to one vote per share and may vote online, by phone, or by mail. The proxy details a board where independent directors form a majority and chair all key committees, and shows significant insider and large‑holder ownership, including 33.31% beneficial ownership by CEO Phillip Frost, M.D.